| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24c8e25c9e764f8fcb4d26cf5a8c96c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f4e9e11f80c79c7145ddafe5f70e242 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00 |
| filingDate |
2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1c2b2d0bf1909d221c9d19a0103044b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a62291f8d74a15ae5b179491008a1e80 |
| publicationDate |
2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012088272-A1 |
| titleOfInvention |
Methods and compositions combining immunotherapy with monocyte activation |
| abstract |
Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting BI O cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting BI O cells may be a CD 19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B I O cells are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11179417-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10017739-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10611999-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019211492-A1 |
| priorityDate |
2010-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |